Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Carlton, Australia Clinical Trials

A listing of Carlton, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (674) clinical trials

Collection and Characterization of Objective Measures to Explore the Specificity of Algorithms

The aim of this descriptive study is to collect and describe the characteristics of objective measures to explore the specificity of algorithms.

Phase N/A

0.0 miles

Learn More »

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

HYPER-2, will be a cross-section study, using the same recruitment and testing strategies used in HYPER 1, which determined the prevalence of anal, genital and oral HPV among men who have sex with men aged 16-20 years. Given the differing age groups that will have been offered vaccination over the ...

Phase N/A

0.17 miles

Learn More »

Cochlear Implant With Anti-Inflammatory Agent

In an effort to further preserve residual acoustic hearing after cochlear implantation, it may be beneficial to incorporate anti-inflammatory agents into the electrode array for passive elution over a time course after implantation. This study aims to assess the ease and effectiveness of such an electrode design, and to assess ...

Phase N/A

0.17 miles

Learn More »

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase.

Phase

0.17 miles

Learn More »

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Consenting participants will be screened and within 14 days randomly allocated to receive either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the week 12 visit, patients ...

Phase

0.17 miles

Learn More »

Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination

Males aged 17 to 19 in Australia will be recruited from 2014. Men will undergo sampling from the penis for HPV. The prevalence of HPV infection will be determined in 2014-2015 and compared to the prevalence in 2016-2017.

Phase N/A

0.17 miles

Learn More »

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Phase

0.17 miles

Learn More »

Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Phase

0.17 miles

Learn More »

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Phase

0.17 miles

Learn More »

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

Phase

0.17 miles

Learn More »